Eli Lilly and Company is one of the leading pharmaceutical companies in the U.S.. The new president of intercontinental operations were re-evaluation of all parts of the company, including a joint venture with Ranbaxy Laboratories Limited, one of the largest pharmaceutical companies in India. This joint venture was run smoothly for years, despite their difference in focus, but recently Ranbaxy experienced cash flow difficulties associated with its international sales network. In addition, the Indian government changed the rules of business in India and accession to the World Trade Organization will have an impact on India's chemical and drug regulations. The president must determine if it is an international joint venture continues to meet the strategic goals of Eli Lilly. "Hide
by Charles Dhanaraj, Paul Beamish, Nikhil Celly Source: Richard Ivey School of Business Foundation 25 pages. Publication Date: May 25, 2004. Prod. #: 904M16-PDF-ENG
Related Case Solutions & Analyses:
The New Value Imperative for Privately held companies: The Why What and How of value Management Strategy
Disaster By Design: Californias Experience with Electricity Restructure: The Storm Hits (B)
Deere & Co. Worldwide Logistics
Life as a Minor League CEO: Frank Burke and the Chattanooga Lookouts
Volant Skis
The Natural Step
Engineering Inspection & Insurance Co.
Andina Bottling
adidas Group: IT Multi-Sourcing at adidas
New York City’s Teen ACTION Program: an Evaluation Gone Awry
